Abstract：
UNASSIGNED: Response rates of approved systemic therapies for cutaneous T-cell lymphoma (CTCL) hover near 30%, suggesting unmet need. This study describes real-world treatment patterns and response rates of extracorporeal photopheresis (ECP) in CTCL patients.
UNASSIGNED: A chart review was conducted in the United States of adults with CTCL who initiated ECP between January 1, 2017, and February 28, 2019, and received at least three months of ECP treatment as monotherapy or concomitant therapy. Clinical outcomes were collected quarterly for up to 18 months.
UNASSIGNED: The 52 patients were predominantly Caucasian. Half were male; median age was 69 years. Most patients had Sézary syndrome (50%) or mycosis fungoides (36.5%). Nearly 40% of patients had stage IV disease; 33% had lymph node involvement. Nineteen patients (36.5%) achieved response (>50% reduction in BSA affected); median time to response was 6.5 months. The percentage of patients rated as at least minimally improved was 59.5% at 6 months (N = 22), 75.0% at 9 months (N = 24), and 60.0% at 12 months (N = 15) after ECP initiation.
UNASSIGNED: Despite the ECP treated population in this study being older and having more advanced-stage disease than recent trials, response rates were comparable. These real-world findings support ECP as an effective treatment option for CTCL patients.
UNASSIGNED: A chart review was conducted in the United States of adults with CTCL who initiated ECP between January 1, 2017, and February 28, 2019, and received at least three months of ECP treatment as monotherapy or concomitant therapy. Clinical outcomes were collected quarterly for up to 18 months.
UNASSIGNED: The 52 patients were predominantly Caucasian. Half were male; median age was 69 years. Most patients had Sézary syndrome (50%) or mycosis fungoides (36.5%). Nearly 40% of patients had stage IV disease; 33% had lymph node involvement. Nineteen patients (36.5%) achieved response (>50% reduction in BSA affected); median time to response was 6.5 months. The percentage of patients rated as at least minimally improved was 59.5% at 6 months (N = 22), 75.0% at 9 months (N = 24), and 60.0% at 12 months (N = 15) after ECP initiation.
UNASSIGNED: Despite the ECP treated population in this study being older and having more advanced-stage disease than recent trials, response rates were comparable. These real-world findings support ECP as an effective treatment option for CTCL patients.
摘要：
■经批准的皮肤T细胞淋巴瘤（CTCL）全身疗法的反应率徘徊在30％左右，暗示未满足的需求。这项研究描述了CTCL患者体外光置换（ECP）的真实世界治疗模式和反应率。
在美国对2017年1月1日至2019年2月28日期间开始ECP并接受至少3个月ECP治疗的CTCL成人进行了图表回顾。每季度收集临床结果，为期18个月。
■52例患者主要为白种人。一半为男性；中位年龄为69岁。大多数患者患有Sézary综合征（50％）或真菌病（36.5％）。近40％的患者患有IV期疾病；33％的患者有淋巴结受累。19名患者（36.5％）获得了响应（受影响的BSA减少>50％）；中位响应时间为6.5个月。在6个月（N=22）时，被评为至少最小改善的患者百分比为59.5％，9个月时75.0%（N=24），ECP开始后12个月（N=15）为60.0%。
尽管本研究中接受ECP治疗的人群比最近的试验年龄更大，并且患有更晚期的疾病，反应率相当。这些真实世界的发现支持ECP作为CTCL患者的有效治疗选择。
在美国对2017年1月1日至2019年2月28日期间开始ECP并接受至少3个月ECP治疗的CTCL成人进行了图表回顾。每季度收集临床结果，为期18个月。
■52例患者主要为白种人。一半为男性；中位年龄为69岁。大多数患者患有Sézary综合征（50％）或真菌病（36.5％）。近40％的患者患有IV期疾病；33％的患者有淋巴结受累。19名患者（36.5％）获得了响应（受影响的BSA减少>50％）；中位响应时间为6.5个月。在6个月（N=22）时，被评为至少最小改善的患者百分比为59.5％，9个月时75.0%（N=24），ECP开始后12个月（N=15）为60.0%。
尽管本研究中接受ECP治疗的人群比最近的试验年龄更大，并且患有更晚期的疾病，反应率相当。这些真实世界的发现支持ECP作为CTCL患者的有效治疗选择。
